BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

American Express earnings accelerate to 28 percent as discount revenue and credit quality improve

Moe Alsumidaie by Moe Alsumidaie
October 26, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

American Express reported third-quarter net income of $3,712 million, up 28 percent from $2,902 million in the same quarter last year, as discount revenue climbed 8 percent and provisions for credit losses fell 23 percent. The company did not issue forward guidance in the filing.

Discount revenue, the largest revenue stream, reached $10,169 million in Q3’26, compared with $9,413 million in Q3’25. Net card fees grew faster, rising 16 percent to $2,969 million from $2,551 million. Total non-interest revenues climbed 8 percent to $15,122 million. Net interest income expanded 10 percent to $4,940 million as interest on card balances rose 7 percent to $6,387 million, while interest expense fell 10 percent to $1,918 million as deposit costs declined 9 percent.

Year-to-date through Q3’26, net income attributable to common shareholders reached $9,663 million, up 17 percent from $8,272 million in the same nine-month period of 2025. Total revenues net of interest expense and provisions climbed 12 percent to $55,286 million. Diluted earnings per share rose 20 percent to $14.22 for the nine-month period, compared with $11.85 last year.

What it means

The earnings acceleration outpaced revenue growth, driven by two structural shifts. First, credit quality improved sharply: provisions for card credit losses fell to $895 million from $1,220 million year-over-year, a 27 percent decline that suggests either tighter underwriting, lower delinquency rates, or both. The company’s filing does not specify which. This credit benefit alone accounts for roughly half the earnings beat, since the provision line moved faster than revenues.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: AMERICAN EXPRESS CO and 500+ other names, on the same official data.See the evidence engine →

Second, the company’s funding costs compressed. Deposit interest expense fell 9 percent despite customer deposits rising 3 percent to $155,019 million, indicating either a shift in deposit mix toward lower-cost products or a lag in rate repricing as the Federal Reserve began cutting rates in September 2024. Long-term debt interest also fell 11 percent. This funding advantage is temporary: as deposit rates reset downward, the margin benefit will fade unless card yields rise or volumes accelerate further.

Card balances grew 8 percent to $233,153 million, matching network volume growth of 8 percent, suggesting the company is not gaining share through volume alone. Billed business (the broadest measure of card spending) also grew 8 percent. The company’s return on average equity reached 42.4 percent in Q3’26, up from 35.9 percent in Q3’25, but this metric is inflated by the credit provision benefit and lower funding costs. The honest open question is whether the credit improvement is cyclical (a temporary reprieve in consumer health) or structural (tighter risk management). The filing provides no forward guidance on provisions, credit losses, or loan growth, leaving visibility into normalized profitability unclear.

Operating expenses rose 9 percent to $14,546 million, in line with revenue growth. Card member services costs jumped 36 percent to $2,006 million year-over-year, the largest expense acceleration, though the filing does not explain the driver. Salaries and benefits rose 15 percent, outpacing revenue growth and suggesting wage pressure or higher headcount.

What to watch

The next quarterly earnings release will reveal whether credit provisions normalize or remain depressed, and whether deposit funding costs begin to rise as rate cuts persist. Watch for management commentary on card member services cost inflation and any forward guidance on loan growth or credit losses. The company’s capital ratios remain well above regulatory minimums, with Common Equity Tier 1 at 10.9 percent, leaving room for increased shareholder returns if earnings sustain.

Source: the company’s 8-K filed 2026-10-23 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on American Express: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: American Express.

BullScope TerminalYou just read AMERICAN EXPRESS CO’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

AbbVie: The Company That Owed More Than It Owned, and Kept Growing Anyway

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Visa’s Margin Pause: What the Latest Quarter Actually Says

September 23, 2026

Halozyme: The Royalty Machine Trading at a Premium to Its Own History

September 9, 2026

Bank of America Is Priced for a Bank It Has Never Quite Been

August 14, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.